|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash and cash equivalents | |||||
| Restricted cash | |||||
| Inventory | |||||
| Account receivables | |||||
| Total current assets | |||||
| Long term deposits | |||||
| Property and equipment, net | |||||
| Operating right-of-use asset | |||||
| Intangible assets | |||||
| Goodwill | |||||
| Investment in JV | |||||
| Investment in marketable securities | |||||
| Total non-current asset | |||||
| Total assets | |||||
| Operating lease liability | |||||
| Short-term loans | |||||
| Trade payables | |||||
| Other payables | |||||
| Total current liabilities | |||||
| Long-term loans | |||||
| Total non-current liabilities | |||||
| Total Liabilities | |||||
| Common stock of $0.001 par value - Authorized: 250,000,000 and 100,000,000 shares as of December 31,2022 and 2021; Issued and outstanding: 1,464,117 and 959,297 as of December 31,2022 and 2021, respectively | |||||
| Additional paid-in capital | |||||
| Accumulated other comprehensive loss | |||||
| Accumulated deficit | |||||
| Total shareholders’ equity | |||||
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Other income | |||||
| Impairment of goodwill | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Financial income (expense), net | |||||
| Equity loss of equity method investees | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Net loss for the year | |||||
| Other comprehensive income (loss): | |||||
| Foreign currency translation differences | |||||
| Total comprehensive loss | |||||
| Basic loss per share | |||||
| Diluted loss per share | |||||
| Basic weighted average number of shares outstanding | |||||
| Diluted weighted average number of shares outstanding | |||||
Loading...